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Abstract 21 
Objective: To review the efficacy of functional electrical stimulation (FES) used for foot drop in people with multiple sclerosis 22 
(pwMS) on gait speed in short and long walking performance tests.  23 
Data sources: Five databases (Cochrane Library, CINAHL, Embase, MEDLINE, Pubmed) and reference lists were searched. 24 
Study selection: Studies of both observational and experimental design where gait speed data in pwMS could be extracted were 25 
included.  26 
Data extraction: Data were independently extracted and recorded. Methodological quality was assessed using the Effective Public 27 
Health Practice Project (EPHPP) tool. 28 
Data synthesis: Nineteen studies (described in 20 articles) recruiting 490 pwMS were identified and rated moderate or weak, with 29 
none gaining a strong rating. All studies rated weak for blinding. Initial and ongoing orthotic and therapeutic effects were assessed 30 
 with regards to the impact of FES on gait speed in short and long walking tests. Meta-analyses of the short walk tests revealed a 31 
significant initial orthotic effect (t = 2.14, p = 0.016) with a mean increase in gait speed of 0.05 meters per second (m/s) and 32 
ongoing orthotic effect (t = 2.81, p = 0.003) with a mean increase of 0.08m/s. There were no initial or ongoing effect on gait speed 33 
in long walk tests and no therapeutic effect on gait speed in either short or long walk tests. 34 
Conclusions: FES used for foot drop has a positive initial and ongoing effect on gait speed in short walking tests. Further fully-35 
powered randomized controlled trials comparing FES with alternative treatments are required.  36 
 37 
Key words: Review, Multiple Sclerosis, electric stimulation, gait disorders/neurologic, walking 38 
 39 
Abbreviations: 40 
AFO Ankle Foot Orthosis 41 
EPHPP Effective Public Health Practice Project 42 
FES Functional Electrical Stimulation 43 
m/s meters per second 44 
MS Multiple Sclerosis 45 
NICE National Institute for Health and Care Excellence 46 
 ODFS Odstock Dropped Foot stimulator 47 
pwMS people with Multiple Sclerosis 48 
RCT Randomized Controlled trial 49 
UK United Kingdom 50 
USA United States of America 51 
10MWT 10 meter walk test 52 
6MWT 6 meter walkway test 53 
25ftWT 25 foot walk test 54 
2minWT 2 minute walk test 55 
3minWT 3 minute walk test 56 
4minWT 4 minute walk test  57 
5minSSWS 5 minute self selected walk speed   58 
6minWT 6 minute walk test 59 
 60 
 61 
 62 
  63 
Introduction 64 
Multiple Sclerosis (MS), a chronic autoimmune demyelinating central nervous system disease, is the leading cause of disability in 65 
young adults in Western Europe and North America1-4. In 2010, there were an estimated 130,000 cases of MS in the UK, with an 66 
incidence of 11.52 per 100,000 in women and 4.84 per 100,000 in men4.  67 
MS is a progressive disease with accumulation of irreversible neurological deficits, and is characterised by visual, brainstem, 68 
cerebellar, cognitive, motor and sensory symptoms1, 2. Ambulatory impairment is the main contributor to disability within the first 10 69 
years5 with around 75% of people with MS reporting limitations in walking6. Timed walking tests provide a quantitative measure of 70 
walking performance, which have demonstrated good reliability in pwMS7 and are strongly associated with self-reported walking 71 
ability6. Habitual walking performance, described as the number of steps taken in aQLQGLYLGXDO¶VRZQHQYLURQPHQWDFFHOHURPHWU\72 
is predicted by gait speed as measured by a range of walking speed performance tests, making it a valid outcome in interventional 73 
studies8. Walking capacity tests encompass measures of both short (e.g. 10 meter walk test (10MWT)) and longer (e.g. 6 minute 74 
walk test (6minWT)) timed measures of walking9. Short and long walking tests have been found to indicate distinct aspects of 75 
walking. Short walk tests are accurate descriptors of walking capacity and longer walking tests are recommended in interventional 76 
studies9.  77 
 The inability to maintain active ankle dorsiflexion during the swing phase of the gait cycle results in foot drop, impacting on the 78 
energy cost and speed of walking6, instability and falls10. FES is an assistive technology used for foot drop in MS and other 79 
neurological conditions. FES was initially developed for use during gait in 1960 by Liberson et al.11 who demonstrated immediate 80 
benefits on walking in hemiplegic patients. Previous studies have reported effects of FES on gait in people with MS (pwMS) with 81 
reference to walking speed and energy cost12,13. The effects of FES are commonly described in terms of orthotic effects and 82 
therapeutic effects.  An orthotic effect, most frequently reported, refers to the difference in performance between walking with and 83 
without FES. An initial orthotic effect is the immediate change seen with FES on the first day of its use12. An ongoing orthotic effect 84 
is the change in walking with and without FES at a follow up point following a period of regular use12. The therapeutic effect 85 
describes the impact of regular use of FES on walking performance over time and is the difference in walking performance without 86 
FES prior to application compared to a follow up assessment without the device12.  87 
There are a number of commercially available FES devices for clinical application. They all apply electrical stimulation to the 88 
common peroneal nerve, activating ankle dorsiflexion during the swing phase of gait and assisting foot clearance. Stimulation is 89 
synchronised with the gait cycle using a variety of mechanisms employed by the devices including tilt sensors, heel switches, and 90 
wired and wireless technology. Stimulation can be applied externally via surface electrodes or internally via implantable electrodes. 91 
Recent research suggests that implantable devices are as effective as surface stimulation alternatives for pwMS13, although there 92 
are additional risks such as device failure and neuropraxia13.      93 
 A recent narrative review14 described the impact of FES in MS on the speed, kinematic profile and energy cost of walking and with 94 
regards to patient satisfaction and perceived benefits of FES. The review found FES to have beneficial orthotic and training effects 95 
on measures of gait, however not all improvements were statistically or clinically significant. Although the majority of patient 96 
reported data demonstrated positive benefits with FES, there was often no correlation with objective measures of gait. The authors 97 
highlighted areas for further research including comparisons with usual care, e.g. an Ankle-Foot Orthosis (AFO), in addition to 98 
measuring longer term effects and identifying predictors of FES response. A previous systematic review in chronic stroke found 99 
orthotic effects of FES on the speed and physiological cost of walking15. One review undertaking meta-analysis noted significant 100 
orthotic effect on the 10mWT16 and another noted a therapeutic effect on the 6minWT17 using FES for foot drop in stroke. There are 101 
clear differences however between stroke and MS, an autoimmune neurodegenerative disease, with regards to their pathology and 102 
demographic profile that may impact on the effectiveness of FES. There is a growing body of evidence for FES for foot drop in MS, 103 
therefore there is a need for a systematic review to explore the efficacy of the intervention. Thus, the aim was to systematically 104 
review the evidence to date for the orthotic and therapeutic effects of surface and implantable FES used for foot drop in pwMS, with 105 
regards to its impact on gait speed in both short and long walking performance tests.   106 
 107 
Materials and methods 108 
A literature search was conducted on 27th September 2016 by two authors (AS, RH) using a protocol developed a priori.  109 
 Due to the limited number of known controlled trials in this field of study the review was purposefully inclusive, including empirical 110 
research and studies of both observational and experimental design evaluating FES as an intervention. Opinion pieces, narrative 111 
reviews, conference and poster abstracts, and studies not in the English language were excluded. No restrictions were place on 112 
publication date.  113 
Studies on adult participants (>18 years) with a diagnosis of MS were included. Studies investigating a mixed neurological sample 114 
were included where data for pwMS could be extracted separately.  115 
Studies included all types of FES devices for foot drop. Studies investigating other interventions in addition to FES were included 116 
where the other intervention was a comparator group. Studies reporting on device development were excluded.  117 
To be eligible for inclusion studies had to report on a minimum of one measure of gait speed using either short or long walking tests 118 
with and without the device, at a minimum of one time point. Gait speed is described in meters per second (m/s) and measured by 119 
walking over a short distance (e.g.10 meters, 25 feet) or a longer distance (e.g. 2 or 6 Minute Walk) 120 
Search strategy 121 
The following databases were searched: CINAHL via EBSCO, Embase and Medline via OVID, the Cochrane library and PubMed 122 
that included in-process citations. Individual search strategies were conducted in each database using the key search terms, 123 
 Medical Subject Headings and Boolean operators shown in Table 1 and applying the previously agreed eligibility criteria. A hand 124 
search of the reference lists of relevant articles was undertaken.  125 
The search results were exported from the individual database to a specialised referencing software package (REFWORKS) and 126 
duplicates were removed.  Articles were screened by title (AS) and the abstracts were reviewed by two authors (AS, RH). In the 127 
case of disagreement over inclusion at abstract review stage, consensus was reached by consulting a third reviewer (LR). The full 128 
text of articles that met inclusion/exclusion criteria were read and assessed for eligibility.  129 
[Insert table 1 here] 130 
Quality assessment 131 
There is QRµJROGVWDQGDUG
FULWLFDODSSUDLVDOWRROUHFRPPHQGHGLQUHKDELOLWDWLRQUHVHDUFKKRZHYHUDV\VWHPDWLFUHYLHZRf available 132 
critical appraisal tools recommends tools should be selected based on the purpose of the review18. The Effective Public Health 133 
Practice Project (EPHPP) tool19 was selected following consideration of the research question and recommendations from previous 134 
systematic reviews20, 21. The EPHPP tool provides a checklist with a summary score that allows for inclusion of a range of different 135 
study designs within the review. The EPHPP tool has demonstrated good reliability and validity20.  136 
The articles for review were initially identified as either observational or experimental in design using the Scottish Intercollegiate 137 
Guidelines Network algorithm for study design (Figure 1). A pilot quality check was undertaken on one article by all 4 assessors 138 
 (LR, LP, AS, RH) to ensure consistency.  Subsequently 2 reviewers reviewed each article and where there were discrepancies an 139 
agreement was reached via discussion.  140 
Data extraction and analysis 141 
One reviewer (LR) extracted data from the articles on participants (e.g. age, gender, MS type), methods (e.g. study design) 142 
interventions (FES type, description of control intervention) and outcomes (e.g. assessment time points and outcome measures) 143 
and results using an a priori developed data extraction form. A second reviewer (AS) checked the data extracted. Authors were 144 
contacted where further clarification was required around data.    145 
Data, where available, were subjected to meta-analysis as per Everitt22. Data from all 3 short walking tests (10MWT, 25 foot walk 146 
test (25ftWT), 6 meter walkway test (6MWT)) were combined and presented as the primary outcome measure. Data from all the 147 
longer walking tests (2 minute walk test (2minWT), 3 minute walk test (3minWT), 4 minute walk test (4minWT), 6minWT, 5 minute 148 
self-selected walk test (5minSSWS)) were combined and presented as the secondary outcome measure. Justification for combining 149 
data from the longer walking tests was based on previous evidence that noted a strong association between the 2minWT and 150 
6minWT in pwMS23. Initial and continued orthotic and therapeutic effects of FES were analysed. Given the differences in protocol 151 
timings in each study included in the meta-analysis calculations and the lack of randomness, a heuristic approach was taken as no 152 
Odds Ratios were reported. This approach has been previously used in other clinical areas24. All calculations are from baseline 153 
 data given the differences in times between study protocols and, where only sample size, means and standard deviations were 154 
reported, 95% confidence intervals were estimated with the assumption of approximate Normal distributions. The estimates of the 155 
95% confidence intervals of the mean of each outcome variable from each paper and for the pooled samples are presented. For 156 
ongoing orthotic and therapeutic effects, data from studies reporting on the time frame ranging from 2-20 weeks were included for 157 
analysis. There is currently no evidence to suggest when a therapeutic effect may occur following FES application, therefore a 158 
pragmatic approach was taken that combined the minimum and median time frames reported in the papers selected for review.    159 
Results 160 
Literature search 161 
The electronic literature search yielded a total of 125 articles, 8 from CINAHL, 67 from MEDLINE (OVID and EBSO), 29 from 162 
Embase, 7 from Cochrane Library and 14 from PubMed databases.  A hand search of reference lists yielded an additional 11 163 
articles. Once duplicates were removed this yielded 90 articles for screening. The remaining 23 full text articles were reviewed (AS, 164 
RH) and a further 3 were excluded. The remaining 20 articles, reporting on 19 studies involving 490 pwMS met the inclusion criteria 165 
and were included in the quality review and meta-analysis. Results are presented in the PRISMA flowchart (Figure 2).    166 
Study and participant characteristics 167 
 The characteristics of the studies and subjects are presented in Table 2. Eleven articles in the review used experimental designs, 168 
including 1 randomized controlled trial (RCT)25, 1 randomized crossover trial26 and 8 non RCTs generating data in 9 articles27-35. 169 
Nine articles presented data from 8 observational studies, including 1 case control36 and 8 interrupted time series 170 
designs12,13,37,38,40-42. All studies recruited participants from hospitals or MS clinics and most recruited pwMS only13, 25-29, 31-40,42. 171 
Three studies recruited participants with different neurological diagnoses, where MS data could be extracted separately12,30,41. The 172 
20 articles recruited a total of 447 participants. Sample numbers in the majority of studies were generally small and ranged from 242 173 
to 3913, however one retrospective observational study presented data from 153 participants40. Most studies reported either a mix 174 
of MS type or did not report MS type. Two studies recruited participants with secondary progressive MS only25, 26. There were 175 
similarities in the age, sex, time since diagnosis and disability level of the participants recruited across the studies. The mean age 176 
of participants ranged from 46.513 to 5635 years and time since diagnoses ranged from 8.635 up to 17.725 years. Between 25 to 77 % 177 
of participants recruited in the studies were female. Disability was only reported in 6 studies and ranged from Extended Disability 178 
Status Score 3.532 to 5.926 . Walking aid use was frequently reported throughout the studies, indicating that participants had 179 
significant walking impairment.  180 
The detail given about inclusion and exclusion criteria varied. Some observational studies reported minimal detail12,31,37,41,42 other 181 
than the inclusion of MS participants deemed suitable for FES while others12,25,28,30,37,41 did not indicate whether participants had 182 
used FES prior to inclusion. Some studies recruited pwMS already using FES13,29,31,36,38,39,42 while others indicated previous FES 183 
 use as an exclusion26,27,34. Some studies excluded potential participants unable to walk a minimum of 10 meters27, 29, 30, whereas 184 
others included only those able to walk longer distances, up to 6 minutes33,36,38,39,41. Only 4 studies reported exclusion of potential 185 
participants with unstable disease or recent relapse27,33,38,39. Most studies gave no indication of exclusions related to medication. 186 
Only 1 study excluded participants taking medication for fatigue or mobility33; however another27 actively recruited participants on a 187 
stable dose of fampridine, a drug licensed for treating walking impairment in MS.          188 
Interventions 189 
Almost half of the studies investigated the single channel Odstock Dropped Foot Stimulator® (ODFS)a 25,28,29,31,32,35,36,39. Four 190 
articles included data from dual channel ODFS (for bilateral foot drop or foot drop plus gluteal stimulation) in addition to single 191 
channel ODFS12,26,37,40. Three studies evaluated the Walkaide® systemb 27,30,34, one study compared the ODFS with Walkaide® 38 192 
and one study investigated the impact of the Ness L300® devicec 33.  Two studies evaluated implantable FES, one study with the 193 
STIMuSTEPa 13 and another with ActiGait®d 42. The only RCT 25 compared single channel ODFS with an exercise programme. A 194 
randomized crossover trial13 compared single channel ODFS followed by dual channel ODFS (anterior tibialis and guteal 195 
stimulation) with weekly physiotherapy.  A non-randomized controlled trial compared single channel ODFS with an AFO29.   196 
[Insert Table 2 here] 197 
Outcome measures and effects  198 
 Details of the outcome measures used in each of the studies are presented in Table 3. All articles presented data on outcome 199 
measures that assessed gait speed. Seventeen studies measured gait speed over short distances, with most tests indicating 200 
participants walked at a fast pace. The majority of studies used the 10 metre Walk Test (10MWT)12,13,25,27,28-30,32,37,40,41,42 however 3 201 
studies presented data on the 25 foot Walk Test (25ftWT)27,34,35 and two studies reported gait speed over a 6 metre walkway 202 
(6MWT)31,33 as part of 3D gait analysis.  203 
Walking speed over longer distances was less frequently reported. The range of walking tests used include: 6minWT27,28, 204 
5minSSWS36,38,39, 4minWT30, 3minWT13,25 and 2minWT32. Data from the 6minWT and 3minWT are reported as the total distance 205 
walked in the specified time, which was converted to walking speed for the purpose of analysis. All other tests are reported in m/s. 206 
Some articles reported on other aspects of gait, which are described in Table 2, however any further analyses on these measures 207 
are out of the scope of this review and will not be discussed further.   208 
With regards to the short walking tests, all except 2 of the articles29,35 measuring this outcome reported on the initial orthotic effect 209 
of FES. Nine studies reported a statistically significant increase in walking speed following initial application of FES, with effects 210 
ranging from 5 to 18.3%12,26,28,30-32,34,40,41. In contrast, 4 studies found no difference with FES25,27,33,37 and 2 small studies 211 
investigating 242 and 529 participants reported mixed results.  212 
 Thirteen articles reported on ongoing orthotic effects12,13,25,26,29,30,32,33,35,37,40-42 from 4 weeks 29,35 up to a mean of 10.8 years12 post 213 
application. All of the studies except 233,35 evaluating ongoing orthotic effects reported a statistically significant increase in walking 214 
speed.  215 
The therapeutic effect of FES on gait in short walking performance tests was reported in 11 articles12,13,25,26,30,32,33,37,40-42 at a 216 
number of time points from 6 weeks25 to a mean of 10.8 years12 of FES application. One study reported a statistically significant 217 
therapeutic effect at 12 weeks30. The majority of articles found no therapeutic effect with small or no improvements in walking 218 
speed25,26,32,33,37,40. Four of the studies noted a reduction in unassisted walking speed at 1242 and 18 weeks41, and this was  219 
significant in 2 studies at 313 and a mean of 5.1 years12.  220 
Effects of FES on gait in long walking performance tests were reported less frequently. There were mixed results with reports of 221 
initial positive orthotic effects in the 2minWT28,32, 3minWT41and 4minWT31 but not the 6minWT27,28. Positive ongoing orthotic effects 222 
were found from 6 weeks to 11 months13,25,30,32,42. Two studies reported in 3 articles36,38,39 used the same protocol for the 223 
5minSSWS and evaluated the impact of FES on established users of more than 6 months. Both studies noted significant ongoing 224 
orthotic effects, except in participants already walking at baseline speeds of >0.8m/s39.  225 
The therapeutic effect of FES on longer walking tests was investigated in only 5 studies. There were mixed results with positive 226 
effects being noted at 12 weeks30,32 and 11 months30, but not at 1242 and 18 weeks13,25.    227 
 [Insert Table 3 here] 228 
Methodological quality 229 
The methodological quality of the studies is detailed in Table 4. The global rating for methodological quality was moderate for 12 230 
articles12,13,25,26,28,30, 32,34,35,37,40,41 while the remaining 8 articles received a global rating of weak27,29,31,33-36,42. None of the 20 articles 231 
gained an overall strong rating largely due to difficulty blinding participants and assessors with FES. All of the studies scored weak 232 
on blinding thus indicating performance and detection bias. Twelve articles rated strong for data collection methods12,13,25,26,28-233 
30,32,34,36,37,40. One study rated strong for selection bias25, one study rated weak29 and all the others rated moderate. Study design 234 
was rated moderate for all of the studies excluding 2 that were rated weak 29,42. For fifteen articles the confounders variable was not 235 
applicable12,13,28-3,40,42 as there were no comparator control groups.  236 
[Insert Table 4 here] 237 
Analysis of overall effect 238 
Eleven studies recruiting 353 participants were included in the meta-analysis for the initial orthotic effect of FES on gait speed for 239 
short walking speed tests (Table 5). Eight articles with a total of 255 participants were included for meta-analysis of ongoing orthotic 240 
effects (Table 5). Meta-analyses revealed evidence of a significant initial (t = 2.14, p = 0.016) and ongoing orthotic effect of up to 20 241 
weeks (t = 2.81, p = 0.003) using FES for foot drop on gait speed in short walking performance tests in pwMS. Walking speed 242 
 increased by 0.05 meters per second (m/s) (7.1%) for the initial orthotic effect and 0.08m/s (11.3%) and for the ongoing orthotic 243 
effect.  244 
Six studies recruiting 244 participants were included in the meta-analysis for the therapeutic effect of FES on gait speed (Table 5). 245 
Analyses of the pooled data found no change in gait speed in the short walking performance tests and thus no therapeutic effect 246 
(t=0.03, p=0.487) with FES.    247 
Five studies recruiting 89 participants were included in the meta-analysis for the initial orthotic effect on gait speed in long walking 248 
performance tests (Table 6). Eighty one participants were included for analyses of the ongoing orthotic effect of FES. There was a 249 
small non-significant increase in walking speed of 0.02m/s (3.3%) for the initial orthotic (t=0.57, p=0.286) and a small non-250 
significant increase of 0.04m/s (6.2%) for ongoing continued orthotic effect (of up to 20 weeks) (t=0.94, p=0.174) with FES (Table 251 
6).  252 
Only 3 studies recruiting 61 participants included data that was used to evaluate the therapeutic effect (up to 20 weeks) of FES on 253 
gait speed in long walking performance tests. There was a 10.3% increase in walking speed noted, however this was non-254 
significant (t=1.34, p=0.091) (table 6).    255 
[Insert Tables 5 &6 here] 256 
Discussion 257 
 This systematic review aimed to appraise the efficacy of FES for foot drop in pwMS on gait speed in short and long walking 258 
performance tests. A systematic and inclusive approach was undertaken for  study selection, with independent assessment of 259 
quality and data extraction. In this review of 20 articles (19 studies) analysis of pooled data found a statistically significant initial 260 
(t=2.14, p=0.016) and ongoing (t=2.81, p=0.003) orthotic effect of FES on gait speed in short walking performance tests, increasing 261 
gait speed by 0.05 and 0.08m/s, respectively. No  therapeutic effect  was found. A change of 0.05m/s in walking speed is 262 
considered to be clinically significant, with a change of 0.1m/s indicating a substantial clinical change43. Therefore this review 263 
identified effects of FES on walking that are meaningful to pwMS. FES produced small non-significant initial and ongoing orthotic 264 
and therapeutic effects on gait speed in long walking performance tests.  265 
Contradictory results however were found across the studies. The majority of studies reported statistically significant ongoing 266 
orthotic effects for the short walk tests, however 2 studies did not. One of these studies recruited participants with lower disability 267 
scores33. Both studies recruited participants with baseline walking speeds of >0.8m/s (1.2m/s33 and 0.83m/s35). Miller et al.39 had 268 
previously found FES to have no orthotic effect in pwMS walking at gait speeds of >0.8m/s. These results therefore shed some 269 
doubt on the use of FES in pwMS with lower levels of disability and faster baseline walking speeds. Further investigation of FES in 270 
pwMS walking at faster gait speeds is required.  271 
The majority of the studies evaluating therapeutic effects of FES on short walking tests reported no significant difference, however 272 
3 studies reported a negative therapeutic effect13,26,42. One of these studies recruited participants with secondary progressive MS, 273 
 where deterioration in walking speed is expected over time. The other 2 articles investigated implantable FES. Hausmann et al.42, a 274 
study of only 2 participants, reported a negative therapeutic effect in 1 participant. Taylor et al.13 reported therapeutic effects over a 275 
longer time frame (3 years) and although there was no detail given regarding MS type of recruited participants, the time since 276 
diagnosis ( mean of 17.3 years ) is indicative of participants presenting with secondary progressive MS. The results from these 277 
studies suggest that the potential therapeutic effect of FES may be limited in progressive MS patients, however further investigation 278 
is warranted.  279 
The National Institute for Health and Care Excellence (NICE) guidelines for FES for foot drop of central neurological origin44 found 280 
evidence to support the use of FES, however studies included in the NICE review were undertaken  in stroke and not  MS. There 281 
has not been a systematic review specifically evaluating FES in MS although a recent narrative synthesis found positive orthotic, 282 
but not therapeutic effects of FES on walking performance. This review recommended that FES be used to complement treatments 283 
for walking limitation in MS and had potential to optimize functional outcomes14. The results from this systematic review supports 284 
and further strengthens the recommendations of the NICE guidelines and the previous narrative review, by adding further evidence 285 
in terms of the positive impact of FES in MS.  286 
There have been 3 previous reviews of FES in stroke. A narrative synthesis14  reported positive orthotic effects of FES on gait 287 
speed in chronic stroke, although there was less conclusive evidence of a therapeutic effect. Kottink et al.16 reviewed 8 studies and 288 
reported an increase in gait speed of 0.13 m/s (0.07±0.2, 38%) with FES, that is larger than found in this  review for short walk tests 289 
 ( 0.08m/s (-0.01-0.1, 11%)). Pereira et al.17 reviewed 7 RCTs and found a small but significant therapeutic effect with FES (0.379 290 
m/s ± 0.152; 95% CI, 0.081 to 0.677; P = .013) in the 6minWT in chronic stroke. This increase again is more than that found in the 291 
current review for short walk tests (0m/s (-0.06-0.1, no change)); however it may be  that potential therapeutic effects of FES may 292 
be limited by the neurodegenerative nature of MS in comparison to a more acute condition such as stroke and this requires further 293 
investigation.    294 
Participants in the studies reviewed had mean Extended Disability Status Scores ranging from 3.5 (moderate disability in one 295 
functional system and more than minimal disability in several others, no impairment to walking) to 6 (requires a walking aid (cane, 296 
crutch, etc) to walk about 100 meters with or without resting). This sample is representative of pwMS with walking limitations for 297 
whom we would expect a benefit from FES application. Participants in the lower Extended Disability Status Score range (3.5) who 298 
have less obvious walking difficulties however may present with fatigable foot drop. Decreased ankle dorsiflexion at initial contact 299 
has been found to worsen with fatigue45 in pwMS. None of the studies in this review explicitly reported on recruitment of 300 
participants presenting with fatigable foot drop. There is limited evidence that FES may not be beneficial for pwMS with less 301 
disability, walking at faster speeds39   however further investigation is warranted. .    302 
The majority of the articles did not report on MS type which may limit the external validity of the findings of this review, however 2 303 
studies specifically recruited people with secondary progressive MS12, 25. The time since diagnosis was reported in all but 4 of the 304 
articles and ranged between 9.79 to 17.7 years, which may be more indicative of secondary progressive MS.  305 
 Most studies reviewed give little detail around the inclusion and exclusion criteria used and where detail was given there was no 306 
consistent approach taken. The use of medications and the effect of relapse and progression of disease may influence outcomes 307 
and response to FES therefore the failure of most studies to report these variables may call the validity of results of the studies into 308 
question. 309 
There were only two randomized study designs in this review, indicating a high probability of selection bias and poor internal 310 
validity. All studies scored weak for blinding signifying performance and detection bias to be significant factors. It is impossible to 311 
blind physical treatments such as FES to participants and it is extremely difficult to blind assessors. There were no attempts to 312 
separate FES application and outcome assessment in any of the studies, suggesting performance bias. The EPHPP tool considers 313 
both blinding and confounders in its scrutiny therefore both factors impact on the overall quality ratings.    314 
Limitations 315 
The primary limitation of this review was the low methodological quality of the studies included. The conclusions of this review must 316 
therefore be treated with some caution until further high quality RCTs are undertaken. Although the EPHPP quality assessment tool 317 
has demonstrated acceptable levels of test re-test reliability and content and construct validity19, it was developed to evaluate 318 
public health nursing and therefore may not have been the most appropriate tool for this review.  Selection of this tool however was 319 
 based on the recommendations of previous systematic reviews19,20 and supports an inclusive approach which allowed the same 320 
checklist and summary score to be used across all the studies.  321 
This review was limited by the inclusion of English language papers and did not include unpublished studies or studies published in 322 
grey literature which may limit its applicability. There remains a debate around publication bias and the usefulness of including 323 
unpublished trials46, however it is likely that any unpublished studies would be of poor quality and lack robust peer review 46,47.   324 
For the purpose of the meta-analyses data from a range of short and longer walking tests were combined. Although there is 325 
evidence to support the comparability of the longer walking tests23, there are also differences in the pace of the walking tests used  326 
which may have influenced the  results. A recent MS outcome measures taskforce document has also suggested that the 2minWT 327 
should not be used in research due to the limited availability of psychometric data48.  328 
A pragmatic approach was taken which combined data across a range of assessment points (up to 20 weeks) in order to inform 329 
continued orthotic and therapeutic effects. There is no evidence to suggest when optimal orthotic or therapeutic effects are likely to 330 
occur and whether they remain stable over time. Using this approach therefore may have led to ambiguity with the results.    331 
Fewer participants were included in the meta-analyses for the ongoing orthotic (n=81) and therapeutic (n=61) effects of FES on gait 332 
speed on long walking performance tests, therefore there are limitations with regards to the strength of these findings. As no raw 333 
 data was available within group analysis was not viable and the between group analysis may not have detected subtle effects that 334 
may have occurred.   335 
 FES is considered a device that should be used long term for orthotic purposes and in a progressive condition like MS this may 336 
account for many years. Despite this, only one interventional study26 reported on effects beyond 24 weeks, therefore the results of 337 
this review are only applicable over the short to moderate term.   338 
 Implications for further research 339 
Given the low methodology quality of the studies reviewed, future research should focus on adequately powered randomized trial 340 
design with a control or comparator treatment arm, such as exercise or AFO. Improved consistency in reporting of methodology, as 341 
recommended by the CONSORT guidelines49 is also recommended. Consistent reporting of demographics  including MS type, 342 
disability level and baseline walking speed would allow for sub-group analysis. Future studies should include long term follow up 343 
and investigate initial and ongoing orthotic and therapeutic effects of FES in order to understand its full potential as a treatment for 344 
foot drop in MS.      345 
This current review found a wide variation in the walking tests used between studies both in terms of distance, pace (fastest and 346 
preferred) and methods of collection (mean of three, warm up then final test). Researchers should agree on the most valid, reliable 347 
and clinically significant measures of gait speed using short and long walking performance tests to allow a more consistent 348 
 approach in future FES research. This review is limited to the impact of FES on gait speed in short and long walking performance 349 
tests. Some of the articles reported measures of patient experience and quality of life and future studies should consider a mixed 350 
methodological approach as recommended by the NICE guidelines 44.   351 
Conclusion 352 
This review found evidence of initial and ongoing orthotic effects of FES for foot drop in MS on gait speed in short walking tests 353 
which were clinically meaningful, but did not find evidence of orthotic or therapeutic effects of FES on long walking tests. However 354 
due to the poor methodological quality of studies undertaken to date, caution must be applied in making recommendations to 355 
clinical practice. There is limited evidence of the comparative effectiveness of FES with other treatments. Future research should 356 
focus on adequately powered randomized trial design with a control or comparator treatment arm, using valid and reliable 357 
measures of gait speed that can detect clinically meaningful effects.  358 
 359 
Suppliers 360 
a. Odstock Medical Limited, Salisbury, UK 361 
b. Innovative Neurotronics Inc., Austin, TX, USA 362 
c. Bioness Inc., Valencia, CA, USA 363 
 d. Otto Bock Health Care, Duderstadt, Germany 364 
 365 
References  366 
1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517. 367 
2. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952. 368 
3. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; Mar (Clin Res ed) 332(7540):525-7. 369 
4. Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990-2010:a descriptive 370 
study in the general practice research database. J Neurol Neurosurg Psychiatry 2014;85:76-84.  371 
5. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-616. 372 
6. Hobart J, Blight A, Goodman A, et al. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful 373 
in MS. Neurology 2013;80:1509-17. 374 
7. Nilsagard Y, Lundholm C, Gunnarsson LG, et al. &OLQLFDOUHOHYDQFHXVLQJWLPHGZDONWHVWVDQGµWLPHGXSDQGJR¶WHVWLQJLQ375 
persons with multiple sclerosis. Physiother Res Int 2007;12:105±114. 376 
 8. Gijbels D, Alders G, Van Hoof E, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and 377 
self-report measures. Mult Scler 2010;16:618±626. 378 
9. Gijbels D, Dalgas U, Romberg A et al. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing 379 
the basis for a core set. MSJ 2012;18(3):364±371.     380 
10. Gunn H, Creanor S, Haas B, et al. Frequency, characteristics and consequences of falls in multiple sclerosis: findings from a 381 
cohort study. Arch Phys Med Rehabil 2014; 95(3): 538-545. 382 
11. Liberson WT, Holmquest HJ, Scot D, et al. Functional electrotherapy: stimulation of the peroneal nerve synchronized with the 383 
swing phase of the gait of hemiplegic patients. Arch Phys Med Rehabil 1961; 42: 101±5. 384 
12. Taylor P, Humphries L, Swain I. The long-term cost-effectiveness of the use of functional electrical stimulation for the correction 385 
of dropped foot due to upper motor neuron lesion. J  Rehabil Med 2013;45(2):154-160. 386 
13. Taylor PN, Wilkinson-Hart IA, Khan MS, et al. The correction of dropped foot due to multiple sclerosis using the STIMuSTEP 387 
implanted dropped foot stimulator. Int J MS Care In-Press [serial online] 2016. Available from: http://dx.doi.org/10.7224/1537-388 
2073.2015-038  389 
14. Dapul G, Bethoux F. Functional electrical stimulation for foot drop in multiple sclerosis. US Neurology 2015:10-18. 390 
 15. Roche A, Laighin GO, Coote S. Surface-applied functional electrical stimulation for orthotic and therapeutic treatment of drop 391 
foot after stroke: a systematic review. Phys Ther Rev 2009;14(2):63-80. 392 
16. Kottink AIR, Oostendorp LJM, Buurke JH et al. The orthotic effect of functional electrical stimulation on the improvements of 393 
walking in stroke patients with a dropped foot: a systematic review. Artif Organs 2004;28(6):577-86. 394 
17. Pereira S, Mehta S, McIntyre A, et al. Functional electrical stimulation for improving gait in persons with chronic stroke. Top 395 
Stroke Rehabil 2012;19(6):491-8.   396 
18. Katrak P, Bialocerkowski A, Massy-Westropp, et al.  A Systematic review of the content of critical appraisal tools. BMC Medical 397 
Research Methodol 2004 Sep 16;4: 22.    398 
19. Thomas BH, Ciliska M, Dobbins M, et al. A process for systematically reviewing the literature: providing the research evidence. 399 
Worldviews Evid.-Based Nurs 2004;1:176-184. 400 
20'HHNV--'LQQHV-'¶$PLFR5HWDO(YDOXDWLQJQRQ-randomised intervention studies. Health Technol. Assess 2003;7:iii- x, 401 
173. 402 
21. Sanderson S, Tatt DI, Higgans JPT. Tools for assessing quality and susceptibility to bias in observational studies in 403 
epidemiology: a systematic review and annotated bibliography. Int J. Epidemiol 2007;36:666-676. 404 
 22. Everitt, B.S. Cambridge of statistics in the medical sciences. Cambridge UK: Cambridge University Press 1995.  405 
23. Gijbels D, Eijnde BO, Feys P. Comparison of the 2- and 6-minute walk test in multiple sclerosis. Mult Scler 2011;17(10):1269-406 
72.  407 
24. Tomlinson A, Khanal S, Ramaesh K, et al. Tear Film Osmolarity: Determination of a referent for dry eye diagnosis. Invest 408 
Ophthalmol. Vis Sci 2006;47(10).  409 
25. Barrett CL, Mann GE, Taylor PN, et al. A randomized trial to investigate the effects of functional electrical stimulation and 410 
therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler 2009;15:493-504. 411 
26. Taylor P, Barrett C, Mann G, et al. A feasibility study to investigate the effect of functional electrical stimulation and 412 
physiotherapy exercise on the quality of gait of people with multiple sclerosis. Neuromodulation 2014;17:75-84. 413 
27. Mayer L, Warring T, Agrella S, et al. Effects of electrical stimulation on gait function and quality of life for people with multiple 414 
sclerosis taking dalfampridine. Int J MS Care 2015;17:35-41. 415 
28. Scott SM, Van der Linden ML, Hooper JE, et al. Quantification of gait kinematics and walking ability of people with multiple 416 
sclerosis who are new users of functional electrical stimulation. J Rehabil Med 2013;45:364-69.  417 
 29. Sheffler LR, Norgan Bailey S, Chae J. Spatiotemporal and kinematic effect of peroneal nerve stimulation versus an ankle- foot 418 
orthosis: A case series. Am J Phys Med Rehabil 2009a;1:604-11. 419 
30. Stein R, Everaert DG, Thompson AK, et al. Long term therapeutic and orthotic effect of a foot drop stimulator on walking 420 
performance in progressive and non-progressive neurological disorders. Neurorehabil Neural Repair 2010; 24:152-167. 421 
31. Van der Linden M, Scott S, Hooper J, et al. Gait kinematics of people with multiple sclerosis and the acute application of 422 
functional electrical stimulation. Gait Posture 2014a; 39: 1092±1096. 423 
32. Van der Linden M, Hooper J, Cowan P, et al. Habitual functional electrical stimulation therapy improves gait kinematics and 424 
walking performance, but not patient-reported functional outcomes, of people with multiple sclerosis who present with foot-drop. 425 
PLOS ONE 2014(b); 9: 1-9. 426 
33. Barr C, Patritti B, Bowes R, et al. Orthotic and therapeutic effect of functional electrical stimulation on fatigue induced gait 427 
patterns in people with multiple sclerosis. Disabil Rehabil Assist Technol 2016;12(52):1-1331. 428 
34. Downing A, Van Ryn D, Fecko A, et al. Effect of a 2 week trial of functional electrical stimulation on gait function and quality of 429 
life in people with multiple sclerosis. Int J MS Care 2014;16(3):146-152.  430 
 35. Sheffler L, Hennessey M, Knutson J, et al. Neuroprosthetic Effect of peroneal nerve stimulation in multiple sclerosis: a 431 
Preliminary Study. Arch Phys Med Rehabil 2009b;90:362-365. 432 
36. Paul L, Rafferty D, Young S, et al. The effect of functional electrical stimulation on the physiological cost of gait in people with 433 
multiple sclerosis. Mult Scler 2008;14:954-61.  434 
37. Barrett C, Taylor P. The effects of the Odstock drop foot stimulator on perceived quality of life for people with stroke and 435 
multiple sclerosis. Neuromodulation 2010;13:58-64. 436 
38. Miller L, Rafferty D, Paul L et al. A comparison of the orthotic effect of the Odstock dropped foot stimulator and the Walkaide 437 
functional electrical stimulation systems on energy cost and speed of walking in multiple sclerosis. Disabil Rehabil Assist Technol, 438 
2015;10(6):482-85. 439 
39. Miller L, Rafferty D, Paul L et al. The impact of walking speed on the effects of functional electrical stimulation for foot drop in 440 
people with multiple sclerosis. Disabil Rehabil Assist Technol 2016;11(6):478-83.  441 
40. Street T, Taylor P, Swain I. The effectiveness of functional electrical stimulation on walking speed, functional walking category 442 
and clinically meaningful changes for people with multiple sclerosis. Arch Phys Med Rehabil 2015;96(4):667-672. 443 
 41. Taylor P, Burridge J, Dunkerly A, et al. Clinical use of the Odstock dropped foot stimulator: iW¶Veffect on the speed and effort of 444 
walking. Arch Phys Med Rehabil 1999;80:1577-1583. 445 
42. Hausmann J, Sweeney-Reed C, Sobieray U, et al. Functional electrical stimulation through direct 4-channel nerve stimulation to 446 
improve gait in multiple sclerosis: a feasibility study. J Neuroeng Rehabil 2015;12(100):1-9. 447 
43. Pereira S, Mody SH, Woodman RC, et al. Meaningful change and responsiveness in common physical performance measures 448 
in older adults: meaningful change and performance. J Am Geriatr Soc 2006;54:743-749.  449 
44. National Institute for Health and Care Excellence (NICE). Functional electrical stimulation for foot drop of central neurological 450 
origin; interventional procedure guidance. United Kingdom [IPG278] 2009. . 451 
45. McLoughlin JV, Barr CJ, Patritti B et al. Fatigue induced changes to kinematic and kinetic gait parameters following six minutes 452 
of walking in people with multiple sclerosis. Disabil Rehabil. 2016;38:535-543.  453 
46. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. West Sussex: John Wiley & Sons Ltd; 2008. 454 
47. Egger M, Ju¨ni P, Bartlett C, et al. How important are comprehensive literature searches and the assessment of trial quality in 455 
systematic reviews? Empirical study. Health Technology Assessment 2003;7:1. 456 
 48. Potter K, Allen D, Bennett S, et al. Multiple sclerosis outcome measures taskforce [serial online]. Available from: URL:  457 
http://www.neuropt.org/docs/ms-edge-documents/final-ms-edge-document.pdf?sfvrsn=4 458 
49. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. 459 
Ann Intern Med 2010;152:726±732. 460 
  461 
 Figure and table legends 462 
Table1: Search strategy for databases 463 
Database Search Strategy 
CINAHL via 
EBSCO 
0625³PXOWLSOHVFOHURVLV´$1''URSIRRW25IRRWGURS$1'*DLW25ZDON$1')(6
25³IXQFWLRQDOHOHFWULFDOVWLPXODWLRQ´25HOHFWULF25VWLPXODW25³QHXURPXVFXODUHOHFWULFDO
VWLPXODWLRQ´25(0625SHURQHDOQHUYHVWLPXODW 
Cochrane 
Library 
³0XOWLSOH6FOHURVLV´RU06WLDENZDQGIXQFWLRQDOHOHFWULFDOVWLPXODWLRQRU)(6RU
³QHXURPXVFXODUHOHFWULFDOVWLPXODWLRQ´RU³(06´RUHOHFWULFRUVWLPXODWWLDENZRUSHURQHDO
nerve stimulation and Drop foot or foot Drop:ti,ab,kw and gait or walk:ti,ab,kw (Word variations 
have been searched)) 
Embase via 
Ovid 
0625³PXOWLSOHVFOHURVLV´PS$1''URS$1'IRRWPS$1'*DLW25ZDONPS
$1')(625³IXQFWLRQDOHOHFWULFDOVWLPXODWLRQ´25HOHFWULF25VWLPXODW25
³QHXURPXVFXODUHOHFWULFDOVWLPXODWLRQ´25(0625SHURQHDOQHUYHVWLPXODWPS 
MEDLINE 
via Ovid 
0625³PXOWLSOHVFOHURVLV´PS$1''URS$1'IRRWPS$1'*DLW25ZDONPS
$1')(625³IXQFWLRQDOHOHFWULFDOVWLPXODWLRQ´25HOHFWULF25VWLPXODW25
³QHXURPXVFXODUHOHFWULFDOVWLPXODWLRQ´25(0625SHURQHDOQHUYHVWLPXODWPS 
MEDLINE 
via EBSCO 
0625³PXOWLSOHVFOHURVLV´$1''URSIRRW25IRRWGURS$1'*DLW25ZDON$1')(6
25³IXQFWLRQDOHOHFWULFDOVWLPXODWLRQ´25HOHFWULF25VWLPXODW25³QHXURPXVFXODUHOHFWULcal 
VWLPXODWLRQ´25(0625SHURQHDOQHUYHVWLPXODW 
PubMed Multiple sclerosis AND foot drop AND gait AND functional electrical stimulation 
 464 
Table 2: Summary of study design, sample information, outcome measures, assessment points and potential sources of 465 
bias of selected studies.  (key: N=numbers of participants, NR=not reported, pwMS=people with MS, SPMS=secondary 466 
progressive MS, PP=primary progressive, RR=relapsing remitting, DF=dorsiflexion, PF=plantarflexion, EDSS=Extended Disability 467 
 Status Scale, HAI=Hauser Ambulation index, L/L=lower limb, HSP=Hereditary Spastic Paraplegia, FAP=Functional Ambulation 468 
Profile, MSWS-12=Multiple Sclerosis Walking Scale-12, MSIS-29=Multiple Sclerosis Impact Scale-29, PIADS=Psychological 469 
Impact of Assistive Device Scale,SF-36= short form-36, FWC=Functional Walking Category, PCI=Physiological Cost Index, 470 
ROGA=Rivermead Observational Gait Analysis, s=seconds, m=meters, ft=feet, wks=weeks, min=minute, mths=months, 471 
meds=medications)   472 
Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
Barr et al.25 
Experimental: 
non-RCT 
11 
NR 
47 
7:4 
NR 
3.5 
Inclusions 
('66VFRUH-6 
8QLODWHUDOIRRWGURS 
$EOHWRZDONIRUPLQ 
Exclusions 
5HODSVHPR 
T=Ness L300 
NR 
0, 8 6MWT 
None 
Gait analysisf 
6PDOOVDPSOH 
1DUURZ('66UDQJH 
"HIIHFWRIIDVWEDVHOLQH
walking speeds 
$VVHVVRUVQRWEOLQGHG 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
)DWLJXHRUPRELOLW\
medications 
&RQWUDLQGLFDWLRQVWR
FES 
5HJXODUO\XVHV$)2 
8QDEOHWRDFKLHYH
passive DF to 
plantigrade 
Barrett et al26 
Experimental: 
RCT (FES vs 
exercice) 
20 (T: n=20; C: 
n=24) 
SPMS 
T: 52.1±6.7; C: 
56.6±9 
T: 15/5; C: 
16/8 
T: 13.6 (8.3); 
C: 17.7 (8.3) 
T: 5.9 (0.8); C: 
5.8 (0.8) 
Inclusions 
!\ 
6306 
('66VFRUH±6.5 
8QLODWHUDOIRRWGURS 
3DVVLYH')WR
plantigrade 
T=ODFS, 
C=home exercises 
T=unrestricted 
daily use after 
2wk, C=exercises 
performed daily 
(30min) 
0, 6, 12, 18 10MWT 
3minWT 
PCI (10m) 
+LJKGURSRXWUDWH 
1REDVHOLQHDVVHVVPHQW
without FES 
$VVHVVRUVQRWEOLQGHG 
$VVHVVRUVSURYLding 
treatment (measurement 
bias) 
8QGHUSRZHUHG 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
*RRGUHVSRQVHWR)(6 
Exclusions 
2WKHUQHXURRUWKR
problem affecting gait 
&RJQLWLYHSV\FKLDWULF
problem affecting 
compliance 
3RWHQWLDOIRUIDWLJXH
during longer walking 
tests 
Barrett and 
Taylor27 
Observational: 
interrupted time 
series 
20 
NR 
56±6.9 
12:8 
10.7 (7.7) 
NR 
SZ06DWWHQGLQJ)(6
clinic from January 
2005±January 2006 
T=ODFS (n=16), 
dual channel (n=4) 
Unrestricted use 
0, 18 10MWT 
None 
PIADS 
&OLQLFDODXGLWGDWD 
6PDOOVDPSOH 
$VVHVVRUVQRWEOLQGHG 
3RWHQWLDOELDVIURP
questionnaires being 
administered by clinical 
staff providing treatment 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
Downing et al28 
Experimental: 
non-RCT 
19 
RR: n=10; SP: 
n=5; PP: n=4 
51.8±10.2 
10:9 
9 (7,9) 
NR 
Inclusions 
$EOHWRZDONIW!V
and <45s 
1RWFXUUHQWO\XVLQJ)(6 
Exclusions 
5HODSVHG 
5HTXLUHV$)2IRU
stance 
(SLOHSV\ 
3UHYLRXVERWXOLQXPWR[LQ
in L/L last 6mo 
%DFORIHQSXPSODVWPR 
3HULSKHUDOQHUYHLQMXU\ 
T=WA 
Gradual build up 
to full-time wear 
over 2wk 
0, 2 25ftWT 
None 
MSWS12, MSIS29 
6PDOOFRQYHQLHQFH
sample 
1REOLQGLQJRU
comparator 
/LPLWHGIROORZ-up period 
Hausmann et al29 
Observational: 
2 
SP: n=1; PP: 
n=1 
Inclusions ActiGait 0, 12 10MWT 
3minWT 
)HDVLELOLW\VWXG\FDVH
report of 2 participants 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
interrupted time 
series 
49.5 
1:1 
10.5 
5 
3UHYLRXVVXUIDFH)(6
benefits noted but 
sensory side effect not 
tolerated/difficulty 
positioning electrodes 
Gait analysis,fSF-
36 
Mayer et al30 
Experimental: 
non-RCT 
20 
RR: n=8; SP: 
n=8; PP: n=4 
51.7 
12:8 
15.8 
NR 
Inclusions 
6WDEOHGRVHRI
fampridine for 12wk 
/HJZHDNQHVVVORZ
gait, and foRWGURSí
PF during swing) 
$EOHWRZDONIW!V
and <45s 
1RWFXUUHQWO\XVLQJ)(6 
Exclusions 
5HODSVHG 
T=WA 
Daily walking 
í2, 0, 4, 12 25ftWT 
6minWT 
GAITRitei, FAP, 
MSWS12, SF-36 
6PDOOVDPSOH 
&RQYHQLHQFHVDPSOH 
3RVVLEOHFRQFXUUHQWRU
enhanced effect of 
fampridine 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
5HTXLUHV$)2IRU
stance 
(SLOHSV\ 
3UHYLRXVERWXOLQXPWR[LQ
in L/L last 6mo 
%DFORIHQSXPSODVWPR 
3HULSKHUDOQHUYHLQMXU\ 
Miller et al31 
Observational: 
interrupted time 
series 
20 
RR: n=9; SP: 
n=9; PP: n=2 
50.4±7.3 
10:10 
11.2 (8.6) 
EDSS NR but 
HAI between 2 
and 7 
Inclusions 
(VWDEOLVKHG)(6XVHU
(>6mo) 
&DQZDONIRUPLQ 
+$,±6 
Exclusions 
5HFHQWUHODSVHZN 
T=ODFS 
compared with 
walkaidec 
One off 
application only 
0 (variable 
length of using 
FES [mean, 2 
y; SD, 5.75]) 
None 
5minSSWS 
Energy cost of 
walkingg 
6PDOOVDPSOH 
6LQJOHYDULDEOH
assessment time point 
5HFUXLWPHQWRI
established FES users 
SZ06KDGOLPLWHGWLPH
to adapt to 
walkaidecapplication 
$VVHVVRUVQRWEOLQGHG 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
2WKHUQHXURRUWKR
condition affecting gait 
Miller et al32 
Observational: 
interrupted time 
series 
Post hoc analysis 
of Miller et al 
(analysis of 2 
groups based on 
walking speed) 
20 (group 1 
[n=11]: 
<0.8m/s; group 
2 [n=9]: 
>0.8m/s)  
RR: n=9; SP: 
n=9; PP: n=2  
50.4±7.3  
10:10  
11.2 (8.6)  
5.3 (2) 
Inclusions 
(VWDEOLVKHG)(6XVHU
(>6mo) 
&DQZDONIRUPLQ 
+$,±6 
Exclusions 
5HFHQWUHODSVHZN 
2WKHUQHXURRUWKR
condition affecting gait 
T=ODFS 
One off 
application only 
0 (variable 
length of using 
FES [mean, 2 
y; SD, 5.75]) 
None 
5mSSWS 
Energy cost of 
walkingg 
6PDOOVDPSOH 
6LQJOHYDULDEOH
assessment time point 
5HFUXLWPHQWRI
established FES users 
$VVHVVRUVQRWEOLQGHG 
Paul et al33 
Observational: 
case-control 
24 (T: n=12; C: 
n=12 [healthy 
matched 
controls]) 
RR: n=2; SP: 
n=10 P 
Inclusions 
±65y 
T=ODFS 
One off 
application only 
0 (variable 
length of FES 
use 7mo±7y) 
None 
5minSSWS 
Energy cost of 
walkingg 
6PDOOVDPSOH 
6LQJOHYDULDEOHWLPH
point 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
53±8 
NR 
9.8 
NR 
(VWDEOLVK)(6XVHU
(>6mo) 
Exclusions 
2WKHUQHXURRUWKR
condition affecting gait 
5HFUXLWment of 
established FES users 
$VVHVVRUVQRWEOLQGHG 
Scott et al34 
Experimental: 
non-RCT 
12 
NR 
47.8±6.6 
3:9 
NR 
NR 
Inclusions 
±70y 
2EVHUYDEOHIRRWdrop, 
suitable for FES 
Exclusions 
3UHJQDQWRUEUHDVW
feeding (patients 
experiencing a relapse 
were withdrawn) 
T=ODFS 
Initially 4x visits 
separated by >3 
but <14d, then 
habitual use 
0 (0±14d: 
mean of 4 
walks within 
initial 14d) 
10MWT 
6minWT 
Gait analysisf 
6PDOOVDPSOH 
/DUJH6'VRIUHVXOWV 
$FXWHDSSOLFDWLRQRQO\ 
3RVVLELOLW\RIHIIHFWRI
fatigue on walking tests 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
Sheffler et al35 
Experimental: 
non-RCT 
5 
NR 
50 
3:1 
11.8 
NR 
Inclusions 
'LDJQRVHG!PR 
')VWUHQJWKRQ05& 
3UHYLRXVO\XVHG$)2 
$EOHWRZDONIW 
8VHG)(6IRUminimum 
of 4wk 
Exclusions 
1RVHQVDWLRQRQ// 
3)FRQWUDFWXUH 
$WD[LD 
2WKHUQHXURFRQGLWLRQ 
6HYHUHFRJQLWLYH
impairment 
T=ODFS 
One off 
application only 
4 10MWT 
NR 
Gait analysisf 
 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
0HGLFDOQHXURLQVWDELOLW\ 
Sheffler et al36 
Experimental: 
non-RCT 
11 
NR 
52.1± 12 
8:3 
8.6 (4.4) 
NR 
Inclusions 
'LDJQRVHG >6mo 
3UHYLRXVO\XVHG$)2
>3mo 
8VHG)(6IRUPLQLPXP
4wk 
Exclusions 
1RVHQVDWLRQRQ// 
3)FRQWUDFWXUH 
2WKHUQHXURFRQGLWLRQ 
6HYHUHFRJQLWLYH
impairment 
0HGLFDOQHXURLQVWDELOLW\ 
T=ODFS 
Maximum 8h/d for 
4wk 
4 25ftWT 
NR 
mEFAP 
6PDOOFRQYHQLHQFH
sample 
1REOLQGLQJRU
comparator 
2QO\RIWKRVH
screened found eligible 
"VHQVLWLYLW\RI20V 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
Stein et al37 
Experimental: 
non-RCT 
31 (results 
reported for 22, 
which includes 
1 HSP) 
NR (diagnosed 
>6mo) 
54.2±9.9 
15:16 
11.5 (8.7) 
NR 
Inclusions 
)RRWGURS 
!PRGLDJQRVHG 
$GHTXDWHFRJQLWLYHDQG
communication function 
$EOHWRZDONP 
Exclusions 
3RRUUHVSRQVHWR)(6 
!IDOOSHUZHHN 
6HYHUHFDUGLDF
disease/pacemaker 
3)FRQWUDFWXUH! 
:DONLQJVSHHG!PV 
8QDEOHWRRSHUDWH)(6 
T=WA 
Unlimited daily 
use 
0, 4, 8, 12, 48 
Reported at 0, 
12, 48wk 
10MWT 
4minWT 
PCI (10m) 
 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
7HUPLQDOLOOQHVV 
Street et al38 
Observational: 
interrupted time 
series 
187 (153 
analyzed at 
20wk) 
NR 
55 
117:70 
11.7 
NR (EDSS>7) 
Inclusions 
5HIHUUHGVDPSOHLVVXHG
FES (2008±2013) 
Exclusions 
8QDEOHWRZDONP 
3RRUO\FRQWUROOHG
epilepsy 
)L[HGVNHOHWDOGHIRUPLW\ 
&DUGLDFSDFHPDNHU 
T=ODFS (n=178) 
dual channel (n=9) 
NR 
0, median 20 
(interquartile 
range, 16±24) 
10MWT 
NR 
Clinically 
meaningful 
change in walking 
speed, change in 
FWC, reasons for 
not using 
 
Taylor et al42 
Observational: 
interrupted time 
series 
23 
NR 
55.8±9.1 
NR 
14.6 (12.5) 
Inclusions 
8QLODWHUDO foot drop 
5HVSRQVHWR)(6 
T=ODFS 
NR 
0, 18 10MWT 
NR 
PCI (10m) 
6PDOOVDPSOH 
&OLQLFDODXGLWGDWD 
$OWHUHG3&,SURWRFRO"
validity 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
NR (walks a 
min of 10m) 
$EOHWRZDONPDQG
sit-stand unaided 
7ROHUDWHVVHQVDWLRQ 
8QGHUVWDQGV)(6XVH 
Taylor et al12 
Observational: 
interrupted time 
series 
39 
NR 
50.4±9.1 
25:13 
13.5 (8.4) 
NR (mean 
walking 
distance able 
100m) 
Inclusions 
5HIHUUHGVDPSOHSZ06
who received FES in 
1999) 
T=ODFS or dual-
channel stimulator 
NR 
XSWR
10.8y 
10MWT 
NR 
Clinically 
meaningful 
change in walking 
speed 
5HWURVSHFWLYHFOLQLFDO
audit 
1REOLQGLQJFRPSDUDWRU
or randomization 
Taylor et al39 
Experimental: 
individual RCT 
(crossover) 
26 (group 1: 
n=12; group 2: 
n=14) 
SPMS: n=26 
Group 1: 
54.6±9.4; 
Inclusions 
6306 
('66VFRUH 
8QLODWHUDOIRRWGURS 
T=ODFS and 
dual-channel 
ODFS (DF and 
glutes) 
Daily use 
í4, 0, 6, 12, 
18, 24 
10MWT 
NR 
ROGA, MSIS29, 
fall frequency 
6PDOOVDPSOH 
"comparability of the 2 
groups 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
group 2: 
56.9±7.8 
Group 1: 8:4; 
group 2: 10:4 
Group 1: 12.2 
(8.6); group 2: 
14.5 (7.5) 
Group 1: 5.4; 
group 2: 5.9 
*OXWHDOZHDNQHVV
(MRC) and instability of 
trunk, pelvis, or hip 
1RWXVHG)(6
previously 
(IIHFWLYHUHVSRQVHWR
FES 
Exclusions 
5HGXFHGFRJQLWLRQ
affecting compliance 
&RH[LVWLQJPHGLFDO
condition affecting gait 
8QDEOHWRZDONZLWKRXW
FES/AFO 
)HDVLELOLW\VWXG\QRWIXOO\
powered 
$VVHVVRUQRWEOLQGHG 
Taylor et al13 
Observational: 
23 (20 included 
in analysis) 
NR 
56.5±11.3 
Inclusions 
5HIHUUHGIRU670X67(3
between 2006 and 2013 
T=STIMuSTEPb 0 (mean, 
128d) 
10MWT 
3minWT 
5HWURVSHFWLYHFOLQLFDO
audit 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
interrupted time 
series 
NR 
17.3 (11.5) 
NR 
$EOHWRZDONPLQLPXP
10m 
([WHUQDO)(6XVHGIRU
minimum of 6mo 
Exclusions 
&RQWUDLQGLFDWLRQVIRU
external FES 
'LDEHWHV*$ULVN
currently on 
immunosuppressant 
drugs 
PCI, SF-36, 
PIADS 
6HOHFWLRQRISDUWLFLSDQWV
í lack of generalizability 
of results 
0LVVLQJGDWD 
1REOLQGLQJFRPSDUDWRU
or randomization 
1RFRPSDULVRQZLWK
predevice walking 
1RGLVWLQFWIROORZ-up 
period for direct 
comparison 
Van der Linden 
et al40 
Experimental: 
non-RCT 
Some of the 
participants were 
recruited from 
22 (T [pwMS]: 
n=22; C [age 
matched 
healthy 
controls]: 
n=11) 
NR 
49.4±7 
Inclusions 
8VLQJ)(6IRUZN 
T=ODFS 
One off 
application only 
0 6MWT 
NR 
Gait analysisf 
6PDOOVDPSOH 
8QGHUSRZHUHG 
0DWFKHGFRQWUROVGLGQRW
walk at range of speeds 
of pwMS 
 Reference and 
Design 
Sample 
Information: 
No. of pwMS 
(T, treatment 
group; C, 
control) 
MS Type 
Age (mean ± 
SD, where 
available) (y) 
Sex (F:M) 
Time Since 
Diagnosis (y)  
EDSS 
Sample Information Intervention 
Frequency of 
Use 
Assessment 
Points 
Reported (wk) 
Outcome 
Measures: 
Short Walk Test 
Long Walk Test 
Other 
Limitations/Potential 
Sources of Bias/Other 
Comments 
Scott et al34 (ie, 
12 of the total 22) 
11:11 
NR 
NR 
"DIIHFWRIZDONLQJDLGV
in treatment group 
8QEOLQGHGDVVHVVRUV 
Van der Linden 
et al41 
Experimental: 
non-RCT 
9 
NR 
53±9 
7:2 
NR 
NR 
Inclusions 
±75y 
2EVHUYDEOHIRRWGURS 
3DVVLYH')WR
plantigrade at ankle 
Exclusions 
:HDNQHVVLQORZHUOLPE
(unable to bend/hold leg 
in supine) 
1RWZDONLQJLQWKH
community 
)L[HG//GHIRUPLW\ 
T=ODFS 
NR 
í4, 0, 6, 12 10MWT 
2minWT 
RPE, Gait 
analysis,fdaily step 
count,hMSIS29, 
FSS, MSWS12 
6PDOOsample 
8QGHUSRZHUHGSLORW
study 
1RFRQWUROJURXS 
$VVHVVRUQRWEOLQGHG 
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 Table 3: Summary of outcome measures used, effects measured (initial, ongoing and therapeutic) and results for gait 474 
speed in short walking performance tests (10 meter walk test (10MWT), 25 foot walk test (25ftWT), 6 meter walk test 475 
(6MWT)) and long walking performance tests (6 minute walk test (6minWT), 5 minute self-selected walking speed 476 
(5minSSWS), 4 minute walk test (4minWT), 3 minute walk test (3minWT) and 2 minute walk test (2minWT)). (.H\ĹLQFUHDVH477 
ĻGHFUHDVHVLJ VWDWLVWLFDOO\VLJQLILFDQW QRWVWDWLVWLFDOO\VLJQLILFDQW15 QRWUHSRUWHGP PHWHUVV VHFRQGVPV PHWHUVSer 478 
second, wks=weeks, mths=months). 479 
Article Short Walking 
Performance 
Tests 
Test Used 
Pace/Measured 
in 
Other Details 
Orthotic Effect Therapeutic 
Effect 
Long 
Walking 
Performance 
Tests 
Test Used 
Measured in 
Other 
Details 
Orthotic Effect Therapeutic 
Effect (8±
20wk) Initial Ongoing 
(up to 
20wk) 
Initial Ongoing (up to 
20wk) 
Barr et al25 6MWT 
SSWS, m/s 
Mean of 3 trials 
כSig diff 
with FES 
כSig diff 
with FES 
כSig diff with 
FES 
NR NR NR NR 
Barrett 
et al26 
10MWT 
SSWS (m/s) 
כSig diff 
with FES 
6LJĹZLWK
FES at 6, 
12, 18wk 
(P=.001) 
כSig diff with 
FES at 18wk 
3minWT 
Distance 
walked, m 
NR 6LJĹZLWK)(6
at 6 (P=.01), 12 
(P=.003), and 
18wk (P=.004) 
כSig diff with 
FES 
Barrett 
and 
Taylor27 
10MWT 
Pace NR, m/s 
כSig diff 
with FES 
6LJĹZLWK
FES at 
18wk 
(P=.001) 
כSig diff with 
FES 
NR NR NR NR 
Downing 
et al28 
25ftWT 
Fastest safe 
6LJĹZLWK
FES 
NR NR NR NR NR NR 
 Article Short Walking 
Performance 
Tests 
Test Used 
Pace/Measured 
in 
Other Details 
Orthotic Effect Therapeutic 
Effect 
Long 
Walking 
Performance 
Tests 
Test Used 
Measured in 
Other 
Details 
Orthotic Effect Therapeutic 
Effect (8±
20wk) Initial Ongoing 
(up to 
20wk) 
Initial Ongoing (up to 
20wk) 
speed/s 
Mean of 2 trials 
(P=.0004, 
18.3%) 
Hausmann 
et al29 
10MWT 
Pace NR, m/s 
Patient 
1: כSig 
diff with 
FES 
Patient 2: 
6LJĹZLWK
FES 
(P=.006) 
Patient 
1: כSig 
diff with 
FES 
Patient 2: 
6LJĹZLWK
FES 
(P=.006) 
at 12wk 
3DWLHQWĻ
walking 
speed 
without FES 
at 12wk 
Max distance 
walked, m 
Patient 
6LJĹ
with 
FES 
(P=.022) 
Patient 
6LJĹ
with 
FES 
(P=.04) 
Increase in 
walking distance 
with FES 
compared with 
without FES at 
12wk 
Therapeutic 
effect noted 
in both 
patients 
Mayer 
et al30 
25ftWT 
Pace NR, ft/s 
Screening 
without 
FES=baseline 
without FES 
כSig diff 
with FES 
NR NR 6minWT 
Distance 
walked, m 
כSig diff 
with 
)(6Ĺ
10%) 
NR NR 
Miller 
et al31 
NR NR NR NR 5minSSWS 
SSWS, m/s 
NR 6LJĹZLWK2')6
(P=.043) 
1RQVLJĹZLWK
walkaidec(P=.06) 
NR 
Miller 
et al32 
NR NR NR NR 5minSSWS 
SSWS, m/s 
NR 6LJĹZLWK)(6
(P=.043) 
6LJĹZLWKVORZ
walkers 
(<0.8m/s) 
(P=.005) כSig effect with 
NR 
 Article Short Walking 
Performance 
Tests 
Test Used 
Pace/Measured 
in 
Other Details 
Orthotic Effect Therapeutic 
Effect 
Long 
Walking 
Performance 
Tests 
Test Used 
Measured in 
Other 
Details 
Orthotic Effect Therapeutic 
Effect (8±
20wk) Initial Ongoing 
(up to 
20wk) 
Initial Ongoing (up to 
20wk) 
fast walkers 
(>0.8m/s) 
Paul 
et al33 
NR NR NR NR 5minSSWS 
SSWS, m/s 
NR 6LJĹZLWK)(6
(P=.004; 15.1%) 
NR 
Scott 
et al34 
10MWT 
Time to walk, s 
6LJĹZLWK
FES 
(P=.004) 
NR NR 6minWT 
Distance 
walked, m 
כSig diff 
with 
FES 
NR NR 
Sheffler 
et al35 
10MWT 
SSWS, m/s 
NR Variable 
response. 
1 out of 5 
noted sig 
ĹZLWK
FES at 
4wk 
NR NR NR NR NR 
Sheffler 
et al36 
25ftWT 
Pace NR, s 
NR כSig diff 
with FES 
at 4wk 
NR NR NR NR NR 
Stein 
et al37 
10MWT 
Maximal safe 
speed, m/s 
6LJĹZLWK
FES 
(P<.001; 
3.9%) 
6LJĹZLWK
FES 
(P<.001; 
6.7%) at 
12wk 
1RQ6LJĹ
at 11mo 
(4.1%) 
6LJĹZLWK
FES (P<.001; 
5.3%) at 
12wk 
Non Sig 
effect at 
11mo (5.6%) 
4minWT, m/s 
Max safe 
walking 
speed 
6LJĹ
with 
FES 
(P<.001; 
2.3%) 
6LJĹZLWK)(6
(P<.001; 5.7%) 
at 12wk and 
11mo (4.8%) 
NR 
Street 
et al38 
10MWT 
Pace NR, m/s 
3 walks, fixed 
6LJĹZLWK
FES 
(P<.001; 
14%) 
6LJĹZLWK
FES at 
20wk 
כSig diff with 
FES 
NR NR NR NR 
 Article Short Walking 
Performance 
Tests 
Test Used 
Pace/Measured 
in 
Other Details 
Orthotic Effect Therapeutic 
Effect 
Long 
Walking 
Performance 
Tests 
Test Used 
Measured in 
Other 
Details 
Orthotic Effect Therapeutic 
Effect (8±
20wk) Initial Ongoing 
(up to 
20wk) 
Initial Ongoing (up to 
20wk) 
order: warm-up, 
without/with 
(P<.001; 
27%) 
Taylor 
et al42 
10MWT 
Brisk pace, m/s 
Mean of 3 
with/3 without 
randomized 
order 
6LJĹZLWK
FES 
(P<0.01; 
5%) 
6LJĹ
10MWT 
(P<.05; 
16%) with 
FES at 
18wk 
NoQVLJĻDW
18wk (7%) 
NR NR NR NR 
Taylor 
et al39 
10MWT 
Pace NR, m/s 
No. of walks NR 
6LJĹZLWK
FES 
(P<.0001; 
16.2%) 
6LJĹZLWK
FES at 
ZN
(P<.0001; 
15.4%) 
6LJĻDW
ZN
(P<.08) 
NR NR NR NR 
Taylor 
et al13 
10MWT 
Briskly but 
safely, 2 walks 
without followed 
by 2 walks with 
FES, m/s 
NR 6LJĹZLWK
FES at 
18wk 
(P<.001) 
and 3y 
(P<.004) 
כSig effect 
with FES at 
38wk; 
however 3 
GLGDFKLHYHĹ
of 16.67% 
6LJĻ
unassisted 
walking 
speed at 3y 
(P=.14) 
3minWT 
Walking 
along a 14-m 
corridor, pace 
NR, m 
NR 6LJĹZLWK)(6
at 18wk 
(P<.001) 
ĻLQ
unassisted 
walking 
speed at 
18wk 
Taylor 
et al12 
10MWT 
Pace NR, m/s 
Mean of 3 walks 
with/without 
FES 
6LJĹZLWK
FES 
(group 1) 
(P=.06) כSig diff 
6LJĹZLWK
FES 
(group 1) 
(6wk) 
(P=.06) 
כSig effect 
with FES 
NR NR NR NR 
 Article Short Walking 
Performance 
Tests 
Test Used 
Pace/Measured 
in 
Other Details 
Orthotic Effect Therapeutic 
Effect 
Long 
Walking 
Performance 
Tests 
Test Used 
Measured in 
Other 
Details 
Orthotic Effect Therapeutic 
Effect (8±
20wk) Initial Ongoing 
(up to 
20wk) 
Initial Ongoing (up to 
20wk) 
with FES 
(group 2) 
Van der 
Linden 
et al40 
6MWT 
SSWS, m/s 
6 walks with, 6 
walks without 
FES, barefoot 
6LJĹZLWK
FES 
(P=.039) 
NR NR NR NR NR NR 
Van der 
Linden 
et al41 
10MWT 
Pace NR, 
Mean of 2 walks 
with and without 
FES 
6LJĹZLWK
FES 
(P=.006) 
6LJĹZLWK
FES at 6 
and 12wk 
(P=.006) 
ĹDWZN
(8.2%, 
Cohen d<.29) 
2minWT 
Distance 
walked (m) 
6LJĹ
with 
FES 
(P=.002) 
6LJĹZLWK)(6
at 6 and 12wk 
(P=.002) 
ĹDWZN
Cohen d<.29) 
 480 
Table 4: Methodological quality assessment using the Effective Public Health Practice Project (EPHPP) tool 481 
Study Selection 
Bias 
Study 
Design 
Confounders Blinding Data Collection 
Methods 
Withdrawals Global 
Rating 
Barr et al25 Moderate Moderate N/A Weak Weak Strong Weak 
Barrett et al26 Strong Moderate Strong Weak Strong Strong Moderate 
Barrett and 
Taylor27 
Moderate Moderate N/A Weak Strong Strong Moderate 
Downing et al28 Moderate Moderate N/A Weak Strong Strong Moderate 
 Study Selection 
Bias 
Study 
Design 
Confounders Blinding Data Collection 
Methods 
Withdrawals Global 
Rating 
Hausmann 
et al29 
Moderate Weak N/A Weak Strong Weak Weak 
Mayer et al30 Moderate Moderate Weak Weak Weak Strong Weak 
Miller et al 
201431 
Moderate Moderate N/A Weak Weak Strong Weak 
Miller et al 
201532 
Moderate Moderate Strong Weak Weak Strong Weak 
Paul et al33 Moderate Moderate N/A Weak Weak N/A Weak 
Scott et al34 Moderate Moderate N/A Weak Strong N/A Moderate 
Sheffler et al35 Weak Weak N/A Weak Strong Strong Weak 
Sheffler et al36 Moderate Moderate N/A Weak Strong Moderate Moderate 
Stein et al37 Moderate Moderate N/A Weak Strong Strong Moderate 
Street et al38 Moderate Moderate N/A Weak Strong Moderate Moderate 
Taylor et al42 Moderate Moderate Weak Weak Moderate Strong Moderate 
Taylor et al12 Moderate Moderate N/A Weak Strong Strong Moderate 
Taylor et al39 Moderate Strong Strong Weak Strong Strong Moderate 
Taylor et al13 Moderate Moderate N/A Weak Strong Strong Moderate 
Van der Linden 
et al40 
Moderate Moderate N/A Weak Weak Strong Weak 
Van der Linden 
et al41 
Moderate Moderate N/A Weak Strong Strong Moderate 
 482 
 Table 5: Initial and ongoing orthotic and therapeutic effects for combined short walking performance tests (*ft/s converted 483 
to m/s where required, + no FES OFF data reported)  484 
Study Gait Speed for Combined Short Walking Performance Tests (m/s)כ 
Initial Orthotic Ongoing Orthotic Therapeutic 
No FES FES No FES FES No FES 
(Baseline) 
No FES 
Barr et al25 1.18±0.17 
(11) 
1.17±0.17 
(11) 
1.20±0.19 
(11) 
1.25±0.19 
(11) 
1.18±0.17 (11) 1.20±0.19 
(11) 
Barrett et al26 0.79±0.16 
(20) 
0.79±0.15 
(20) 
0.73±0.16 
(20) 
0.80±0.16 
(20) 
0.79±0.16 (20) 0.73±0.16 
(20) 
Downing et al28 0.46±0.17 
(19) 
0.56±0.13 
(19) 
NR NR NR NR 
Mayer et al30 0.56±0.15 
(20) 
0.55±0.17 
(20) 
NR 0.67±0.12 
(20) 
NR NR 
Scott et al34 0.79±0.25 
(11) 
0.83±0.25 
(11) 
NR NR NR NR 
Sheffler et al36 NR NR 0.83±0.16 
(11) 
0.82±0.21 
(11) 
NR NR 
Stein et al37 0.78±0.13 
(30) 
0.81±0.15 
(30) 
0.82±0.15 
(30) 
0.88±0.14 
(30) 
0.78±0.13 (30) 0.82±0.15 
(30) 
Street et al38 0.72±0.05 
(153) 
0.79±0.05 
(153) 
0.72±0.06 
(153) 
0.82±0.05 
(153) 
0.72±0.05 (153) 0.72±0.06 
(153) 
Taylor et al42 0.52±0.10 
(21) 
0.54±0.10 
(21) 
0.48±0.10 
(21) 
0.57±0.11 
(21) 
0.52±0.10 (21) 0.48±0.10 
(21) 
Taylor et al12 0.49±0.09 
(39) 
0.55±0.10 
(39) 
NR NR NR NR 
Van der Linden et al40 0.74±0.20 
(20) 
0.80±0.21 
(20) 
NR NR NR NR 
 Study Gait Speed for Combined Short Walking Performance Tests (m/s)כ 
Initial Orthotic Ongoing Orthotic Therapeutic 
No FES FES No FES FES No FES 
(Baseline) 
No FES 
Van der Linden et al41 0.79±0.15 (9) 0.86±0.12 (9) 0.89±0.15 (9) 0.94±0.16 (9) 0.79±0.15 (9) 0.89±0.15 (9) 
Average results from 
available data 
0.69±0.03 
(353) 
0.74±0.03 
(353) 
0.74±0.04 
(255) 
0.82±0.04 
(255) 
0.74±0.04 (244) 0.74±0.04 
(244) 
 485 
Table 6: Initial and ongoing orthotic and therapeutic effects for combined long walking performance tests 486 
Study Gait Speed for Combined Long Walking Performance Tests (m/s)כ 
Initial Orthotic Ongoing Orthotic Therapeutic 
No FES FES No FES FES No FES 
(Baseline) 
No FES 
Barrett et al26 0.55±0.11 
(20) 
NR 0.62±0.14 
(20) 
0.69±0.15 
(20) 
0.55±0.11 (20) 0.62±0.14 
(20) 
Mayer et al30 0.60±0.12 
(20) 
0.59±0.23 
(20) 
NR 0.66±0.11 
(20) 
NR NR 
Scott et al34 0.82±0.11 
(8) 
0.80±0.09 
(8) 
NR NR NR NR 
Stein et al37 0.53±0.08 
(32) 
0.54±0.08 
(32) 
0.58±0.10 
(32) 
0.61±0.09 
(32) 
0.53±0.08 (32) 0.58±0.10 
(32) 
Van der Linden et al41 0.84±0.15 
(9) 
0.87±0.14 
(9) 
0.88±0.17 
(9) 
0.92±0.19 
(9) 
0.84±0.15 (9) 0.88±0.17 
(9) 
Average results from 
available data 
0.61±0.05 
(89) 
0.63±0.05 
(69) 
0.64±0.07 
(61) 
0.68±0.05 
(81) 
0.58±0.06 (61) 0.64±0.07 
(61) 
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  488 
Figure 1: SIGN algorithm for classifying study design 489 
  490 
Figure 2: PRISMA flowchart demonstrating identification process for systematic review 491 
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